source
- Claris Bio raises $118M Series B and appoints new CEO to advance eye-drug for limbal stem cell deficiencyClaris Bio, a New Jersey biotechnology company, announced a $118 million Series B financing round co-led by Samsara BioCapital and Catalio Capital Management, with participation from Sofinnova Inve…
- GSK announces $2.5 billion annual cost-cutting plan to offset upcoming patent cliffGSK disclosed in its latest quarterly earnings that it will launch a three-year restructuring aimed at saving about £1.9 billion ($2.5 billion) each year. The plan is intended to cushion the impac…